Background {#Sec1}
==========

Premature ovarian failure (POF), also called *premature ovarian insufficiency*, is a challenging reproductive issue causing loss of ovarian function in women younger than 40 years of age \[[@CR1]--[@CR5]\]. Despite intense research, the causes of POF remain a mystery in most cases \[[@CR3], [@CR6]\]. POF is characterized by hypoestrogenism; increased serum gonadotropin levels; and, most important, amenorrhea \[[@CR1], [@CR3], [@CR5], [@CR6]\]. POF affects about 1--3% of women in the general population \[[@CR7]\], but its prevalence is up to 10--28% in females with primary amenorrhea and about 4--18% in women with secondary amenorrhea \[[@CR7]\]. POF is a devastating diagnosis for women of reproductive age \[[@CR2]\]. Ovaries of patients with POF are characterized by loss of secondary follicles and arrested folliculogenesis, which leads to a decrease or elimination of estrogen production and infertility. The mechanism of the ovarian follicles' depletion in patients with POF is most likely an accelerated follicular atresia, but the detailed pathogenesis is not fully understood yet \[[@CR8]\]. In addition, estrogens are essential for normal folliculogenesis beyond the antral stage \[[@CR9]\] and are known to be decreased in patients with POF. Also, POF is associated with serious health consequences, including psychological distress, osteoporosis, autoimmune disorders, ischemic heart disease, Alzheimer disease, metabolic syndrome, diabetes, and increased risk of mortality \[[@CR2]\].

For patients with POF who desire pregnancy, the only current option is to receive donor eggs. Recently, several lines of preclinical evidence suggest that cell therapy (CT) using bone marrow--derived mesenchymal stem cells (BMSCs) \[[@CR10]\] can restore the structure and function of injured ovarian tissues \[[@CR11]--[@CR14]\]. CT is based on groundbreaking scientific discoveries and technological advancements. Most cell-based therapies are currently experimental, with a few exceptions \[[@CR10]\]. CT is defined as the transfer or engraftment of living cells into damaged tissue \[[@CR15]\]. CTs can be classified mainly by the origin of cells (autologous or allogeneic transplant) or by their treatment indications (for example, hematological, reproductive, or neurological pathologies). The most common type of CT is the replacement of mature cells through blood and platelet transfusions. Other potential therapeutic applications of CT include treating urinary problems or infectious diseases; rebuilding damaged cartilage in joints; and helping patients with neurological disorders, brain or spinal cord injuries, heart disease, diabetes \[[@CR16]\], and, more recently, cancer \[[@CR17]\].

Human stem cells play a key role and have important potential application in cell-based therapies that represent a possible alternative for a variety of diseases, including reproductive dysfunction. Our preclinical study of POF animal models treated with human BMSCs showed that BMSC-treated animals recovered ovarian function, resulting in folliculogenesis and estrogen production \[[@CR13], [@CR18]\]. In another study, using cisplatin to induce granulosa cell apoptosis, the authors demonstrated that the apoptosis was reduced by BMSCs *in vitro* \[[@CR19]\]. In addition, the MSC treatment group showed increased antral follicle count and estradiol (E2) after 1 month compared with the untreated POF group \[[@CR20]\]. According to these results, BMSCs may potentially revive prematurely failed ovaries in both follicular and hormonal aspects. The role of stem cells in treating diseases is related to their unique regenerative abilities, giving rise to different cells and tissues \[[@CR21]\].

Stem cell therapies can be applied directly, as in the context of bone marrow transplantation, or by the use of more or less mature cells produced *in vitro* from stem cells. Today, donated cells, tissues, and organs from healthy donors are often used to replace diseased or destroyed tissue \[[@CR22]\], but in certain cases, such as in POF, some patients are unwilling to choose this option. Thus, there is a critical need to develop novel effective approaches for POF treatment. In this study, we report early observations of the biological effect of BMSCs as a possible therapeutic tool on the phenotype of POF.

Cases {#Sec2}
=====

Patients were recruited into the study according to the following inclusion criteria: age over 18, primary or secondary amenorrhea at least for 6 months, at least two menopausal follicle-stimulating hormone (FSH) levels (\> 40 IU/L), normal karyotype 46,XX, and presence of at least one ovary. The study was approved by the Augusta University Institutional Review Board (no. 723327-2), and study procedures were initiated only after patients signed informed consent. The inclusion and exclusion criteria are summarized in Table [1](#Tab1){ref-type="table"}. In addition, the hormone levels prior to and 12 months after mesenchymal stem cell injection into the right ovary are summurized in Table [2](#Tab2){ref-type="table"}. Table 1Summary of inclusion and exclusion criteriaInclusionExclusion1. Over the age of 182. Diagnosis of POF (two menopausal FSH levels \> 40 IU/L or primary or secondary amenorrhea at least for 3--6 months)3. Normal karyotype 46,XX4. At least one ovary5. At least unilateral tubal patency6. Acceptable uterine anatomy7. No male infertility8. Normal thyroid function9. Planning and/or willing to attempt to become pregnant as part of the experiment10. No other causes of female infertility1. Currently pregnant or breastfeeding2. History or evidence of current gynecologic malignancy within the past 3 years3. Presence of adnexal masses4. Major mental health disorder5. Active substance abuse or dependence6. Unfit/unwilling to undergo laparoscopy7. Medical conditions that are contraindicated in pregnancy*FSH* Follicle-stimulating hormone, *POF* Premature ovarian failureTable 2Hormone levels prior to and 12 months after mesenchymal stem cell injection into the right ovaryReference rangePreoperative1 week1 month3 months6 months9 months12 monthsP1P2P1P2P1P2P1P2P1P2P1P2P1P2AMH(1.1--53.5 ng/ml)\< 0.0140\< 0.0150.0140\< 0.015\< 0.0140\< 0.015\< 0.014\< 0.015\< 0.1\*\< 0.0140\< 0.015\< 0.1\*FSH(3.0--8.0 IU/L)89.4150.8132161.491.2149.978.1147.168.5\*89.2150.180.3\*LH(2.0--12.0 IU/L)45.867.048.369.536.375.237.367.841.4\*45.071.041.3\*CA 125\< 36 kU/L1110.21320.61312.01110.62.9\*12.3\*Estradiol(27--123 pg/ml)\< 10.896\*19.88\< 5.014.165\< 5.0\< 10.9\< 5.026.15\*21.7910.919.3\*Progesterone(0.1--0.7 ng/ml)0.18870.50.20.2201\< 0.1\< 0.16\< 0.1\< 0.157\*0.2201\< 0.1\*\**Abbreviations: AMH* Anti-Müllerian hormone, *CA 125* Cancer antigen 125, *FSH* Follicle-stimulating hormone, *LH* Luteinizing hormone, *P1* Patient \#1, *P2* Patient \#2\*Data not available

First case {#Sec3}
----------

A 36-year-old Caucasian woman presented with secondary amenorrhea of 4 years' duration. She is a pediatric dentist from the Toronto area in Canada. She was married in 2009 and immediately started using combined oral contraceptive pills for 3 years to delay childbearing. After she stopped taking oral contraceptive pills in January 2012 to attempt pregnancy, her periods never came back, and she had amenorrhea. Her Reproductive Endocrinology and Infertility Physician (REI) diagnosed her with POF FSH (110 IU/L). Since then, she had been treated with hormone replacement therapy (HRT) on and off to control menopausal symptoms. She stopped any external hormones in March 2016 and was only using prenatal vitamins as supplements. She is gravida 0, para 0 (G0 P0). She had menarche at the age of 11. Her menses were regular every 28 days. She denies a history of sexually transmitted disease. She has no other chronic medical conditions, and her past surgical history includes only wisdom teeth removal. She has no known allergies, and she denies use of tobacco, alcohol, or other drugs. Her family history includes only a father with diabetes. Her physical examination showed Tanner stage V with normal anatomy. The complete results of her physical examination are listed in Table [3](#Tab3){ref-type="table"}. The diagnosis of POF was confirmed in May 2012 according to laboratory tests that revealed persistently high serum FSH (110 IU/L) and luteinizing hormone (LH) (53.89 IU/L), as well as low E2 (\< 10 pg/ml). She has a normal karyotype (46,XX) and a negative genetic test result for fragile X syndrome (*FMR1*). She was placed on dehydroepiandrosterone for approximately 6 months, then a follow-up ultrasound examination in July 2013 revealed no antral follicles. She started experiencing menopausal symptoms (hot flushes and vaginal dryness) and received on-and-off HRT for relief from her primary care physician in August 2013. Very rarely, they have found one or two follicles during the cycles, but she did not ovulate. She desired treatment for infertility but refused egg donation for religious reasons. At admission, all her routine preoperative laboratory test results were normal, as listed in Table [3](#Tab3){ref-type="table"}. Table 3Summary of physical examination and laboratory test results at admissionFirst caseSecond casePhysical examinationGeneral: Alert and oriented, no acute distressRespiratory: Lungs are clear to auscultation, respirations are nonlabored, breath sounds are equal, symmetrical chest wall expansionCardiovascular: Normal rate, regular rhythm, no murmur, no gallop, good pulses equal in all extremitiesBreast: No mass, no tenderness, no dischargeGastrointestinal: Soft, nontender, nondistended, normal bowel soundsGenitourinary: Bimanual exam, speculum exam, and external genitalia all WNLMusculoskeletal Normal range of motion Normal strength No tenderness No swellingIntegumentary: Warm, dry, pinkNeurologic: Alert, oriented, no focal deficitsPsychiatric: Cooperative, appropriate mood and affect, normal judgmentGeneral examination: No acute distressEye: Extraocular movements are intact, normal conjunctivaHENT: Normocephalic, normal hearingRespiratory: Lungs are clear to auscultation, respirations are nonlaboredCardiovascular: Normal rate, normal rhythmGastrointestinal: Soft, nondistendedMusculoskeletal: Normal range of motion, normal strengthIntegumentary: Warm, dry, no rashNeurologic: Alert, orientedPsychiatric: Cooperative, appropriate mood and affectAbdominal exam: large midline incision, several small laparoscopic incisionsPelvic exam: External genitalia WNLSpeculum exam: WNL, small pyknotic external osBimanual exam: WNLHematologyWBC 7.0 × 10^3^/mm^3^WBC 5.0 × 10^3^/mm^3^RBC 4.73 × 10^6^/mm^3^RBC 4.37 × 10^6^/mm^3^Hgb 14.1 g/dlHgb 12.5 g/dlHct 42.3%Hct 37.4%MCV 89.4 flMCV 85.7 flMCH 29.7 pgMCH 28.5 pgMCHC 33.3 g/dlMCHC 33.3 g/dlRDW 12.7%RDW 13.8%Platelets 224 × 10^3^/mm^3^Platelets 166 × 10^3^/mm^3^MPV 9.4 flMPV 10.0 flProthrombin time 10.9 secondsProthrombin time 12.0 secondsINR 0.9INR 1.0APTT 35.2 secondsAPTT 29.8 secondsUrine pregnancy test negativeUrine pregnancy test negative*Abbreviations: APTT* Activated partial thromboplastin time, *Hct* Hematocrit, *Hgb* Hemoglobin, *INR* International normalized ratio, *MCH* Mean corpuscular hemoglobin, *MCHC* Mean corpuscular hemoglobin concentration, *MCV* Mean corpuscular volume, *MPV* Mean platelet volume, *RBC* Red blood cells, *RDW* Red blood cell distribution width, *WBC* White blood cells, *WNL* Within Normal Limits, *HENT* Head, Ears, Nose, Throat

Second case {#Sec4}
-----------

A 42-year-old Caucasian woman, G0 P0, presented with secondary amenorrhea. She is a scientist with a doctoral degree at Temple University in Philadelphia with a focus on chronic obstructive pulmonary disease. She presented with high FSH (155 IU/L) and a normal karyotype (46,XX). She had had normal regular menses until 2014. Then, she was diagnosed with a large left ovarian cyst and needed surgery. She underwent robotic laparoscopy, but this had to be changed to midline open laparotomy, and she underwent left oophorectomy and also a myomectomy. After surgery, she had secondary amenorrhea, and she was then diagnosed with POF. She has experienced some menopausal symptoms but denied using any medication for these. She and her husband have been actively trying to achieve a pregnancy through regular intercourse but have not attempted any additional fertility treatments. She had normal hysterosalpingogram and a normal right ovary by ultrasound. Her past medical history only included occasional low blood pressure and remote tonsillectomy. She has no known allergies, and she denies use of tobacco, alcohol, or other drugs. She had a normal physical examination and laboratory workup, the results of which are listed in Table [3](#Tab3){ref-type="table"}. The patient sought infertility treatment but refused egg donation for cultural reasons. She and the patient in case 1 both fit the criteria for inclusion in the present study according to the screening of their medical, surgical, and social histories and physical examinations.

Methods {#Sec5}
=======

Preparation of autologous bone marrow MSC-derived stem cells {#Sec6}
------------------------------------------------------------

With the patients under general anesthesia, the procedure involved the collection of bone marrow tissue from the iliac bone (posterior iliac crest) using a bone marrow aspiration kit soaked in heparin (BD Biosciences, Franklin Lakes, NJ, United States of America (USA)). About 150 ml of marrow tissue was harvested and subjected to concentration. We used a U.S. Food and Drug Administration--cleared class 2 medical Angel device (Arthrex Inc., Naples, FL, USA) that allowed us to concentrate 160 ml of bone marrow aspirate in about 20 minutes. The collected cell pellet was resuspended in 4 ml of bone marrow nucleated cell concentrate (\~ 5 × 10^8^ total nucleated cells and an average of 5--15 million MSCs).

Laparoscopy and direct injection of right ovary {#Sec7}
-----------------------------------------------

We used laparoscopy for direct injection of the harvested BMSCs (4 ml) into the right ovary. A similar amount (4 ml) of normal saline was injected into the left ovary to serve as a control. In case 2, this was not done, because the patient had undergone prior left oophorectomy. Injection was conducted using a 5-mm injector (22-gauge needle). An assistant firmly stabilized the ovary using an atraumatic grasper (Fig. [1](#Fig1){ref-type="fig"}). The surgeon inserted the needle via one entry through the ovarian capsule toward the center of the ovary and slowly injected the cell concentrate over a 5-minute time period to allow gradual expansion of the ovary. After all solution was injected, the needle was left *in situ* for another 5 minutes, acting as a stopper to avoid backflow of injected cells out of the ovary. Fig. 1Ovarian morphologic changes after mesenchymal stem cell injection. **a** Atrophic ovary before injection (*green arrows*) (low magnification). **b** Atrophic ovary before injection (*green arrow*) (zoom-in). **c** Laparoscopic grasper (*green arrow*) to stabilize the ovary during injection process via stem cell injector (*red arrow*). **d** Atrophic ovary (*green arrow*) stabilized in place just before injection process. **e** Injection of the stem cells. **f** Ovary (*green arrow*) near end of injection process (Notice the swelling and apparent increase in ovarian size.)

Transvaginal ultrasound imaging {#Sec8}
-------------------------------

After MSC engraftment, a standard transvaginal ultrasound technique was used for the measurement of endometrial thickness, ovarian volume, and antral follicle count (AFC) at 1 week, 1 month, 3 months, 6 months, 9 months, and 12 months.

Biochemical evaluation of serum hormone levels and symptom evaluation {#Sec9}
---------------------------------------------------------------------

Serum hormone profiles were checked for 1 year postengraftment at 1 week and 1, 3, 6, 9, and 12 months. The examined hormones included FSH, LH, anti-Müllerian hormone (AMH), E2, and progesterone. The serum hormone quantification was done by radioimmunoassay using standard laboratory techniques \[[@CR23]\]. Symptoms were self-reported by both patients to the study coordinators.

Results {#Sec10}
=======

Autologous BMSCs were injected laparoscopically into the right ovary. The left ovary (in the first case) was subjected to sham surgery for control (Fig. [1](#Fig1){ref-type="fig"}). After injection, the volume of the right ovary exhibited a significant increase in size, confirming proper injection and cell delivery inside the ovary. Ovarian volume and hormone levels were monitored at various time points per study protocol; however, several data points were missing in the second case because of noncompliance. Figures [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"} are from the first case. Fig. 2Ovarian volume measured in cubic centimeters after mesenchymal stem cell implantation into ovary of patient 1Fig. 3Serum estrogen level quantified at pre-- and post--mesenchymal stem cell ovarian implantation. The *arrow* indicates the menses that resume within 7 months following mesenchymal stem cell engraftmentFig. 4Serum follicle-stimulating hormone (FSH) level reported pre-- and post--mesenchymal stem cell ovarian implantationFig. 5Serum luteinizing hormone (LH) level examined pre-- and post--mesenchymal stem cell ovarian implantation

First case {#Sec11}
----------

Ovarian volume of the test ovary increased from 0.63 cm^3^ before injection to 2.5 cm^3^ at week 1 of follow-up, then 2.05 cm^3^ 3 weeks later. Follow-up at months 3 and 6 displayed stability in ovarian volume, measuring at 2.3 cm^3^ and 2.7 cm^3^, respectively, with an increase in size after regaining menses at 7 months (Fig. [2](#Fig2){ref-type="fig"}). These data suggest that the right ovary responded specifically to the BMSC injection *in situ*. Furthermore, we noticed an overall increase in serum estrogen level after BMSC engraftment (Fig. [3](#Fig3){ref-type="fig"}). The estrogen level was \< 10.9 pg/ml prior to MSC implantation and 1 week after MSC implantation, and it increased by three times to 20 pg/ml (Fig. [3](#Fig3){ref-type="fig"}). At 6 months after MSC injection, estrogen level reached of 26.1 pg/ml. There were also changes in serum levels of FSH and LH, as shown in Figs. [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"}, respectively, but no changes were observed in serum progesterone levels, anti-Müllerian hormone levels, or antral follicle counts after BMSC implantation compared with preprocedural levels.

Second case {#Sec12}
-----------

We observed an increase in estrogen levels at 9-month follow-up. There were no changes in the FSH, LH, or progesterone levels. Unfortunately, because of this patient's noncompliance, we are missing several data on serum hormone panels. A decrease of menopausal symptoms, such as hot flushes, night sweats, and painful intercourse, was reported by both patients. Both patients reported one incident of menses (3 days of vaginal bleeding, mild to moderate in amount) at 7 months after BMSC implantation.

Discussion {#Sec13}
==========

POF is a devastating medical condition with currently very limited treatment options, which usually fail to address the patients' issues and needs. POF interferes with fertility and causes menopausal symptoms as well as serious psychological sequelae \[[@CR24]\]. All together, these challenges require a multidisciplinary approach in diagnosis and treatment as well as special attention. The current established modalities for treating POF mainly target the hypoestrogenism-related symptoms by using external HRT \[[@CR25]\]. There are no controlled studies regarding the ideal hormone replacement strategy for young women with spontaneous POF \[[@CR26]\]. The absence of evidence-based guidelines regarding the ideal hormone replacement strategy for young women with POF poses a clear challenge.

Spontaneous resumption of ovarian activity is possible in women with POF, indicating that this condition is not irreversible and is likely due to the presence of residual oocytes in these so-called failed ovaries. Women may conceive spontaneously or following different regimens of ovulation induction, thus indicating that ovarian failure is not always permanent \[[@CR27]\]. Recently, *in vitro* maturation (IVM) using ovarian fragmentation combined with Akt stimulation treatment to disrupt ovarian Hippo signaling was developed. A viable birth was reported using IVM followed by *in vitro* fertilization (IVF)-embryo transfer \[[@CR28]\]. In a clinical trial including 14 patients with POF, follicle development waves were detected in 43% of the examined patients. After IVF of retrieved oocytes, four early embryos were derived; one patient became pregnant and delivered a healthy baby boy after embryo transfer \[[@CR29]\]. In another study, ovarian tissue cryopreservation using verification followed by IVM was done for infertility management in 37 patients with POF. The reported results of this study showed that 54% of women had residual follicles and 9 of 20 showed follicular growth with 24 oocytes in autografts retrieved from 6 patients. Following IVF and embryo transfer into four patients, three chemical pregnancies were detected, followed by one miscarriage and two successful deliveries \[[@CR30]\]. This method has multiple limitations, including multiple surgical interventions: one for the collection of the ovarian tissue and another for implantation after IVM and the additional IVF protocols and procedures.

Due to the ability of BMSCs in restoring physiological function of many organs, there are 344 registered clinical trials trying to evaluate the potential of BMSC-based CT against a plethora of human diseases worldwide. BMSCs have been shown to be effective in the treatment of many diseases with the advancement of preclinical studies \[[@CR31]\]. Furthermore, MSCs have been shown in almost all tissues. They can be easily isolated from the bone marrow, adipose tissue, umbilical cord, fetal liver, muscle, and lung and can be successfully expanded *in vitro* \[[@CR32]\]. It is better to use freshly isolated MSCs in stem cell therapy, because it has been shown that major histocompatibility complex II molecules could be increased during *in vitro* expansion of the stem cells, which may increase their allogenicity \[[@CR33]\]. Recent studies have suggested that the allogenicity of MSCs has no significant adverse impact on their engraftment in wound healing, though \[[@CR34]\]. Multiple studies have also demonstrated the ability of stem cell bioactive factors (the secretome) to restore the ovarian function and regeneration \[[@CR35]--[@CR37]\]. Earlier research primarily attributed the effects of the MSC potential therapy to these cells' capacity for local differentiation into various tissue types. However, recently, research studies have indicated that implanted MSCs have short lifespans, and their therapeutic benefits could be due to their secretome \[[@CR38]\]. The secretome is formed of molecules secreted into the extracellular space and consists of soluble proteins, free nucleic acids, lipids, and extracellular vesicles. These vesicles include apoptotic bodies, microparticles, and exosomes. Gu *et al.* studied the reparative effects of MSCs on vascular tissues. They found that two mechanisms are involved in vascular regeneration: the MSCs' multipotent differentiation ability to produce endothelial cells, vascular smooth muscle cells, and other cell types, as well as their capacity to secrete various trophic factors. These factors are potent in promoting angiogenesis, inhibiting apoptosis, and modulating immunoreactions \[[@CR39]\].

The immunomodulatory effect of MSCs works through immune cells such as natural killer (NK) cells, B and T cells, and dendritic cell (DC) differentiation and migration \[[@CR40]\]. Additionally, coculture of the MSC secretome promotes the anti-inflammatory phenotype of DCs, T cells, macrophages, and NK cells \[[@CR41], [@CR42]\]. In addition, the MSC secretome includes a number of molecules, such as prostaglandin E~2~, tumor necrosis factor-α-stimulated gene-6, transforming growth factor-β, hepatocyte growth factor (HGF), and interleukin-10, which may mediate the immunomodulatory function of MSCs \[[@CR43], [@CR44]\]. In the context of POF, the regenerative mechanism of BMSCs in the ovary could be mainly via the promotion of the angiogenesis. Like in other reported models, MSCs produce a large variety of humoral factors that may play a role in tubular formation by recruiting ovarian endothelial microvessel cells \[[@CR45], [@CR46]\]. The data from our experiments in our lab suggest that the MSC secretome can produce similar effects on human granulosa cells *in vitro* \[[@CR47]\]. In a recent publication by our group, Park *et al.* reported that the expression of proliferation marker Ki67 was significantly increased by treatment with the MSC secretome in human ovarian endothelial cells \[[@CR48]\]. MSC secretome treatment also induced significantly higher expression of several angiogenic markers, such as vascular endothelial growth factor (VEGF) receptor 2, Tie2/Tek, VE-cadherin, endoglin, and VEGF, than of matched controls. It suggests that the MSC secretome likely contains bioactive factors that can enhance ovarian angiogenesis. Other studies have indicated that BMSCs are able to differentiate into endothelial cells, pericytes, or even vessel walls to support the formation of blood vessels \[[@CR49]\]. Furthermore, it was suggested that MSCs are also capable of protecting endothelial cells from apoptosis, including oxidative stress--related apoptosis in the initial phase of angiogenesis \[[@CR50]\]. The role of MSCs in promoting angiogenesis was reported in various studies demonstrating that MSCs support the late phases of angiogenesis, including blood vessel maturation \[[@CR51], [@CR52]\]. This is also consistent with our preclinical work where estrogen-responsive organs demonstrated remarkable increases in the mean weight, such as for the ovaries, uterus, kidneys, and liver \[[@CR13]\]. Also, multiple studies demonstrate that transplanted MSCs may play an important role in the ovarian microenvironment paracrine regulation, producing a wide array of cytokines, such as VEGF, insulin-like growth factor-1, and HGF, that inhibit apoptosis \[[@CR53]\].

The results of the first case show that the use of autologous BMSCs injected into the ovaries of patients with POF has a measurable/quantifiable effect with promising results that may make this method a potential treatment option for these patients in the future. In our study, the patients underwent BMSC collection and injection in the same setting while under general anesthesia, which is widely acceptable to patients interested in this trial. In a similar study using MSCs to treat POF, researchers claimed that the use of a similar protocol in patients with POF resulted in spontaneous pregnancy in one patient, but the MSC preparation details, post-procedural serum hormone levels, and imaging data were lacking from that brief report \[[@CR54]\].

Our data show an immediate impact on ovarian volume that persisted throughout the following assessments. There was a consistent and sustained increase in serum estrogen levels through follow-up at 1 week and 1, 3, 6, and 9 months. Such partial correction of a hypoestrogenic state may explain the patient-reported reversal of several menopausal symptoms particularly noticed about 3 months after MSC implantation and onward. Interestingly, there was no increase in the volume of the left control ovary. Both patients reported one incident of spontaneous menses about 7 months after BMSC implantation after several years of absolute amenorrhea, potentially due to the partial correction of E2 hormone levels. Because there was no increase in serum progesterone levels and transvaginal ultrasound (TVS) revealed no detectable antral follicles, one assumes that this anovulatory menstrual bleeding is likely due to the effect of increasing serum estrogen levels on the endometrium after BMSC implantation. These results can be due to the effect of MSCs on the regeneration of the granulosa cells and initiation of folliculogenesis likely up to the secondary follicle stage, which may explain the increase in serum E2 levels with no change in AFC. The increase in size of the right (treated) ovary versus pretreatment size and also compared with the left (control) ovary suggests resumption of folliculogenesis as well as likely stimulated angiogenesis in these injected ovaries. Neither patient seemed to achieve ovulation or reported pregnancies during the 1-year study period. This can be due to a number of factors; for example, the 12-month duration of this trial may not be sufficient to restart the long-stagnant folliculogenesis. Another reason may be the use of autologous MSCs, because several reports have suggested that autologous MSCs from patients with systemic diseases may be suboptimal and possess inferior regenerative abilities compared with such cells from healthy donors \[[@CR55]--[@CR57]\]. Although these early observations are encouraging, we recognize the limitation of our report due to a small number of cases and the lack of several data points from the second case. Our study is active and registered with ClinicalTrials.gov ([www.clinicaltrials.gov/ct2/show/NCT02696889](http://www.clinicaltrials.gov/ct2/show/NCT02696889)) with additional enrollment. Additional research in this area is urgently needed to fully explore the potential of MSCs as a promising treatment for this devastating disease.

Conclusion {#Sec14}
==========

Our study reveals encouraging preliminary data observed after autologous BMSC engraftment into the ovaries of patients with POF. The BMSC delivery into the ovary diminished menopausal symptoms observed at preoperative assessments. The treated patients were able to resume menses within 7 months following MSC engraftment. In addition, no complications or safety concerns were reported in our study. More studies are needed to evaluate this approach, and we will also continue reporting our ongoing clinical trial.
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